Clinical Trial

Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax

Study acronym: ENABLE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Prospective, multi-center, intervention, open clinical trial for the treatment of AML secondary to MPN in patients unfit for intensive chemotherapy investigating a combination regimen including VEN and DEC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-02-19; most recent amendment 2024-11-07.
Status change: Recruiting → Active, Not Recruiting 2024-11-07
Status change: Not Yet Recruiting → Recruiting 2022-01-03
Trial Details
NCT Number NCT04763928
Lead Sponsor Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions Acute Myeloid Leukemia
Enrollment 101 participants
Start Date 2021-12-03
Primary Completion 2024-10-25 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2024-11-08